好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Development of a Scale for Psychosis in Parkinson’s Disease: The Movement Disorders Society- Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Movement Disorders
P11 - Poster Session 11 (11:45 AM-12:45 PM)
17-002
Determine face and content validity of the MDS-PDPRS.
There is no validated clinical outcome assessment designed to measure the functional impact of Parkinson’s disease psychosis (PDP). The MDS-PDPRS is being developed as a clinician-reported outcome assessment to evaluate PDP severity and impact on daily functions and activities. It includes a five-item Diagnostic Screening Questionnaire to identify PDP, followed by a two-part inventory with 14 Likert-type questions for those meeting inclusion criteria: Part 1 – PDP Severity (six items) and Part 2 – Functional Impact (eight items).

Between August 2024 and September 2025, 43 native English-speaking participants from the United States, Nigeria, Australia, and Canada participated in three rounds of virtual cognitive interviewing. The goal was to assess scale clarity, relevance, meaningfulness, completeness and comfort of administration for interviewers, patients, and care partners. Respondents were divided into three groups:

1.     Movement Disorder Specialists (n=11): Evaluated all interview sections and rated the entire MDS-PDPRS.

2.     PDP Patients and Care Partners (n=16 each): Evaluated the Diagnostic Screening Questionnaire and all items through Part 2: PDP Functional Impact.

3.     PD Patients and Care Partners (n=16 each): Evaluated only the Diagnostic Screening Questionnaire.

Patients and care partners were screened for cognition using the Montreal Cognitive Assessment (MoCA) Version 8.1 BLIND (Normal, ≥ 19/22).
MoCA scores ranged from 16 to 22 in PD patients, from 13 to 22 in PDP patients, and from 17 to 22 in care partners. The recommended refinements focus on clarifying medical terminology (severity), modifying transition instructions, and refining instructional wording. Key modifications include refining the symptom recall timeframe, adjusting response options for better accuracy, and reconsidering item relevance (item 7: Ability to Go Outside the Home).
The MDS-PDPRS shows face and content validity for assessing PDP severity and its functional impacts. Clinimetric evaluation is planned as the next step of validation.
Authors/Disclosures
Michelle H. Tosin, PhD, RN (Rush University Medical Center)
PRESENTER 		Dr. Tosin has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuraLight . The institution of Dr. Tosin has received research support from International Parkinson and Movement Disorders Society. Dr. Tosin has received personal compensation in the range of $500-$4,999 for serving as a Consultant with International Parkinson and Movement Disorders Society.
Tiago Mestre, MD, MSC (University of Ottawa) Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CHDI. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Mestre has received research support from CIHR. The institution of Dr. Mestre has received research support from Ontario Research Fund. The institution of Dr. Mestre has received research support from MJFF. The institution of Dr. Mestre has received research support from Parkinson Canada. The institution of Dr. Mestre has received research support from University of Ottawa/PRC.
Glenn T. Stebbins, PhD (Rush University Medical Center) Dr. Stebbins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Stebbins has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Partners Healthcare System. Dr. Stebbins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CHDI. The institution of Dr. Stebbins has received research support from Department of Defense. Dr. Stebbins has received research support from Cleveland Clinic Health Systems. Dr. Stebbins has received personal compensation in the range of $500-$4,999 for serving as a Course Director with MDS.
Graziella Mangone, Sr., MD, PhD Dr. Mangone has nothing to disclose.
Sandra Videmsky Ms. Videmsky has received personal compensation for serving as an employee of International Parkinson and Movement Disorder Society.
Saad Ali, MD Dr. Ali has nothing to disclose.
Jennifer G. Goldman, MD, MS, FAAN Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation Scientific Advisory Board. The institution of Dr. Goldman has received research support from Michael J. Fox Foundation. The institution of Dr. Goldman has received research support from Parkinson's Foundation.
Tien Kheng Khoo, MBBS, PhD Prof. Khoo has nothing to disclose.
Skylar Lewis, BA Ms. Lewis has nothing to disclose.
Pablo Martinez-Martin, MD, PhD Prof. Martinez-Martin has received personal compensation in the range of $500-$4,999 for serving as a Co-Director, Clinical Outcome Assessment Program with Movement Disorder Society.
Oluwadamilola O. Ojo, MD (University of Lagos) Dr. Ojo has nothing to disclose.
Javier Pagonabarraga Javier Pagonabarraga has nothing to disclose.
Anette E. Schrag, MD Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Otsuka. Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merz. Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boehringer ingelheim. Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bial. The institution of Dr. Schrag has received research support from NIHR, EU, Parkinson's UK, MDS.
Daniel Weintraub Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
Christopher Goetz, MD, FAAN (Rush University Medical Center) The institution of Dr. Goetz has received research support from Michael J. Fox Foundation. The institution of Dr. Goetz has received research support from NIH. The institution of Dr. Goetz has received research support from Department of Defense. Dr. Goetz has received publishing royalties from a publication relating to health care. Dr. Goetz has received publishing royalties from a publication relating to health care. Dr. Goetz has received publishing royalties from a publication relating to health care.